GENFIT Says Iqirvo Is First-ever Drug Developed In-house By Company To Achieve FDA Approval; Expects To Receive Milestone Payments From Ipsen
GENFIT Says Iqirvo Is First-ever Drug Developed In-house By Company To Achieve FDA Approval; Expects To Receive Milestone Payments From Ipsen
genfit表示，Iqirvo是公司首個內部研發並獲得美國食品藥品監督管理局批准的藥物；預計將從易生支付里程碑款項。
GENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S., as well as tiered double-digit royalties of up to 20%.
在美國首次商業銷售Iqirvo時，GENFIT有資格獲得來自伊普森的4870萬歐元的里程碑付款，以及高達20%的分層雙位數版稅。
Ipsen's Iqirvo (elafibranor) 80 mg tablets received U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC).
伊普森的Iqirvo（elafibranor）80毫克片劑獲得美國FDA的快速批准，成爲原發性膽汁性肝硬化（PBC）的首個一類治療方法。